The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Which Risk Model Better Identifies High-Risk Smoldering MM?

2.

Study offers clearer picture of childhood brain tumor survival

3.

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

4.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

5.

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot